Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK plc has repurchased 470,000 of its ordinary shares on 19 February 2026 via BNP Paribas under its existing share buyback programme, paying a volume-weighted average price of 2,243.09p and retaining the stock as treasury shares. This latest tranche lifts total shares bought back since 17 February to 1.3 million and leaves GSK with 4,074,951,475 voting shares in issue and 5.92% of its voting rights now held in treasury, a move that marginally enhances earnings per share and may signal continued capital returns discipline to investors.
The company now holds 241,191,094 shares in treasury, and has clarified the new total voting rights figure that shareholders should use for regulatory threshold calculations. By tightening the free float through measured repurchases across London Stock Exchange and Cboe Europe venues, GSK reinforces its active balance-sheet management strategy and provides greater transparency for investors monitoring ownership disclosures under UK market rules.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.
The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a global biopharmaceutical company focused on developing, manufacturing and commercialising prescription medicines and vaccines. The group targets major therapeutic areas including infectious diseases, respiratory conditions, oncology and immunology, and is a longstanding constituent of the UK blue-chip equity market.
Average Trading Volume: 8,824,146
Technical Sentiment Signal: Buy
Current Market Cap: £91.5B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.